Moexipril hydrochloride is a novel ACE inhibitor first marketed in the U.S.A. for
the treatment of hypertension as a monotherapy and as a second-line therapy in
combination with diuretics or calcium antagonists. Like other ACE inhibitors, moexipril
is a prodrug that is converted in the liver to its diacid moexiprilat which is the active
agent. Moexipril displays a higher in vitro inhibitory potency to ACE than enalapril
although its effectiveness in reduction of blood pressure in hypertensive patients is
similar to that seen with enalapril. It is orally active with a rapid onset and prolonged
duration of action. Excellent tolerability has been reported. Moexipril is distinguished
by its lower cost than other marketed ACE inhibitors.
화학적 성질
Crystalline Solid
용도
Angiotensin converting enzyme (ACE) inhibitor; dimethoxy analog of quinapril
위험도
Moderately toxic by ingestion.
생물학적 활성
Angiotensin-converting enzyme (ACE) inhibitor that is hydrolyzed in the liver to the active metabolite moexiprilat (IC 50 values are 2.1 and 2700 nM for moexiprilat and moexipril respectively). Antihypertensive; decreases mean blood pressure in the spontaneous hypertensive rat (SHR). Also blocks degradation of bradykinin into inactive metabolites.